The Impact of COVID-19 on Access to Parkinson's Disease Medication

Julia Ling Yu Cheong; Zhao Hang Keith Goh; Connie Marras; Caroline M. Tanner; Meike Kasten; Alastair J. Noyce

doi:10.1002/mds.28293

The Impact of COVID-19 on Access to Parkinson's Disease Medication

Julia Ling Yu Cheong, Zhao Hang Keith Goh, Connie Marras, Caroline M. Tanner, Meike Kasten, Alastair J. Noyce^*

^*Korrespondierende/r Autor/-in für diese Arbeit

Klinik für Psychiatrie und Psychotherapie

42 Zitate (Scopus)

Abstract

BACKGROUND: Many countries have implemented drastic measures to fight the COVID-19 pandemic. Restrictions and diversion of resources may have negatively affected patients with Parkinson's disease (PD). Our aim was to examine whether COVID-19 had an impact on access to PD medication by region and income. METHODS: This study was conducted as part of a survey sent to members of the Movement Disorders Society focusing on access to PD medication globally. RESULTS: Of 346 responses, 157 (45.4%) agreed that COVID-19 had affected access to PD medication, while 189 (54.6%) disagreed. 22.8% of high-income and 88.9% of low-income countries' respondents agreed that access to PD medication was affected by COVID-19. 59% of all ‘yes' respondents reported increased disability of patients as an impact. CONCLUSIONS: Access to PD medication is likely to have been affected by COVID-19 and result in deterioration of patients' symptomatic control. Resource-poor countries appear to be disproportionately affected compared to more affluent countries.

Originalsprache	Englisch
Zeitschrift	Movement Disorders
Jahrgang	35
Ausgabenummer	12
Seiten (von - bis)	2129-2133
Seitenumfang	5
ISSN	0885-3185
DOIs	https://doi.org/10.1002/mds.28293
Publikationsstatus	Veröffentlicht - 28.08.2020

Fördermittel

The Preventive Neurology Unit is funded by the Barts Charity. Drs Cheong and Goh report no financial disclosures. Dr Marras has received research funding from the Canadian Institutes of Health Research, the Michael J Fox Foundation, the Parkinson's Foundation (US) and Theravance. She receives consulting fees from Grey Matter Technologies. Dr Tanner reports grants from Michael J Fox Foundation, Parkinson Foundation, Gateway LLC, Roche/Genentech, Biogen, Parkinson Study Group, NIH/NIA, NIH/NINDS, VA Merit, Dept of Defense. Personal fees from Biogen Idec, Acorda, Adamas Therapeutics, Amneal, CNS Ratings, Grey Matter LLC, Northwestern University, Guidemark Heallth, Acadia, Neurocrine, Lundbeck, Cadenand Partners, and Harvard U. Non‐financial support from Medtronic, Acadia, Boston Scientific, Neurocrine, Biogen Idec, outside the submitted work. Dr Kasten reports grants from the German Research Foundation. Dr Noyce reports grants from the Barts Charity, Parkinson's UK, Aligning Science Across Parkinson's and Michael J Fox Foundation, and the Virginia Kieley Benefaction. Personal fees/honoraria from Britannia, BIAL, AbbVie, Global Kinetics Corporation, Profile, Biogen, Roche and UCB, outside of the submitted work.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen
SDG 10 – Weniger Ungleichheiten

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

Coronavirus-Bezug

Forschung zu SARS-CoV-2 / COVID-19

Dokumente

10.1002/mds.28293

Weitere Links

Zitieren

@article{8ab1b13d82d04bbebee5a95f363b4cb2,

title = "The Impact of COVID-19 on Access to Parkinson's Disease Medication",

abstract = "BACKGROUND: Many countries have implemented drastic measures to fight the COVID-19 pandemic. Restrictions and diversion of resources may have negatively affected patients with Parkinson's disease (PD). Our aim was to examine whether COVID-19 had an impact on access to PD medication by region and income. METHODS: This study was conducted as part of a survey sent to members of the Movement Disorders Society focusing on access to PD medication globally. RESULTS: Of 346 responses, 157 (45.4\%) agreed that COVID-19 had affected access to PD medication, while 189 (54.6\%) disagreed. 22.8\% of high-income and 88.9\% of low-income countries' respondents agreed that access to PD medication was affected by COVID-19. 59\% of all {\textquoteleft}yes' respondents reported increased disability of patients as an impact. CONCLUSIONS: Access to PD medication is likely to have been affected by COVID-19 and result in deterioration of patients' symptomatic control. Resource-poor countries appear to be disproportionately affected compared to more affluent countries.",

author = "Cheong, \{Julia Ling Yu\} and Goh, \{Zhao Hang Keith\} and Connie Marras and Tanner, \{Caroline M.\} and Meike Kasten and Noyce, \{Alastair J.\}",

note = "{\textcopyright} 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.",

year = "2020",

month = aug,

day = "28",

doi = "10.1002/mds.28293",

language = "English",

volume = "35",

pages = "2129--2133",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley \& Sons Inc.",

number = "12",

}

TY - JOUR

T1 - The Impact of COVID-19 on Access to Parkinson's Disease Medication

AU - Cheong, Julia Ling Yu

AU - Goh, Zhao Hang Keith

AU - Marras, Connie

AU - Tanner, Caroline M.

AU - Kasten, Meike

AU - Noyce, Alastair J.

PY - 2020/8/28

Y1 - 2020/8/28

N2 - BACKGROUND: Many countries have implemented drastic measures to fight the COVID-19 pandemic. Restrictions and diversion of resources may have negatively affected patients with Parkinson's disease (PD). Our aim was to examine whether COVID-19 had an impact on access to PD medication by region and income. METHODS: This study was conducted as part of a survey sent to members of the Movement Disorders Society focusing on access to PD medication globally. RESULTS: Of 346 responses, 157 (45.4%) agreed that COVID-19 had affected access to PD medication, while 189 (54.6%) disagreed. 22.8% of high-income and 88.9% of low-income countries' respondents agreed that access to PD medication was affected by COVID-19. 59% of all ‘yes' respondents reported increased disability of patients as an impact. CONCLUSIONS: Access to PD medication is likely to have been affected by COVID-19 and result in deterioration of patients' symptomatic control. Resource-poor countries appear to be disproportionately affected compared to more affluent countries.

AB - BACKGROUND: Many countries have implemented drastic measures to fight the COVID-19 pandemic. Restrictions and diversion of resources may have negatively affected patients with Parkinson's disease (PD). Our aim was to examine whether COVID-19 had an impact on access to PD medication by region and income. METHODS: This study was conducted as part of a survey sent to members of the Movement Disorders Society focusing on access to PD medication globally. RESULTS: Of 346 responses, 157 (45.4%) agreed that COVID-19 had affected access to PD medication, while 189 (54.6%) disagreed. 22.8% of high-income and 88.9% of low-income countries' respondents agreed that access to PD medication was affected by COVID-19. 59% of all ‘yes' respondents reported increased disability of patients as an impact. CONCLUSIONS: Access to PD medication is likely to have been affected by COVID-19 and result in deterioration of patients' symptomatic control. Resource-poor countries appear to be disproportionately affected compared to more affluent countries.

UR - https://www.scopus.com/pages/publications/85091041274

UR - https://www.mendeley.com/catalogue/d6590f32-6366-3e31-b55b-aaa35973f802/

U2 - 10.1002/mds.28293

DO - 10.1002/mds.28293

M3 - Journal articles

C2 - 32860226

AN - SCOPUS:85091041274

SN - 0885-3185

VL - 35

SP - 2129

EP - 2133

JO - Movement Disorders

JF - Movement Disorders

IS - 12

ER -

The Impact of COVID-19 on Access to Parkinson's Disease Medication

Abstract

Fördermittel

UN SDGs

Strategische Forschungsbereiche und Zentren

Coronavirus-Bezug

Dokumente

Weitere Links

Fingerprint

Zitieren